Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW. Hargrave DR, et al. Among authors: tseng l. Clin Cancer Res. 2019 Dec 15;25(24):7303-7311. doi: 10.1158/1078-0432.CCR-19-2177. Clin Cancer Res. 2019. PMID: 31811016 Clinical Trial.
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.
Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock JA. Kieran MW, et al. Among authors: tseng l. Clin Cancer Res. 2019 Dec 15;25(24):7294-7302. doi: 10.1158/1078-0432.CCR-17-3572. Epub 2019 Sep 10. Clin Cancer Res. 2019. PMID: 31506385 Clinical Trial.
Bridging the Two Worlds: Worldwide Reflections on the 2024 Hong Kong SAR/PolyU Conference.
Yeung JW, Bromley A, Chae Y, Cheung DST, Conboy L, Graca S, Levett K, Lumiere K, Schnyer R, Sparrow K, Tseng L, Yoo J, Zhang YQ, Citkovitz C. Yeung JW, et al. Among authors: tseng l. J Integr Complement Med. 2024 Dec;30(12):1125-1129. doi: 10.1089/jicm.2024.0819. Epub 2024 Nov 11. J Integr Complement Med. 2024. PMID: 39527006 No abstract available.
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Chen CB, et al. Among authors: tseng lc. J Allergy Clin Immunol Pract. 2024 Nov 4:S2213-2198(24)01110-3. doi: 10.1016/j.jaip.2024.10.027. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39505105
1,267 results